tauopathies

Summary

Summary: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.

Top Publications

  1. doi Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
    Diane P Hanger
    MRC Centre for Neurodegeneration Research, King s College London, Institute of Psychiatry, De Crespigny Park, London, SE5 8AF, UK
    Trends Mol Med 15:112-9. 2009
  2. ncbi The role of tau (MAPT) in frontotemporal dementia and related tauopathies
    R Rademakers
    Department of Molecular Genetics, Neurogenetics Group, Flanders Interuniversity Institute for Biotechnology, University of Antwerp, Antwerpen, Belgium
    Hum Mutat 24:277-95. 2004
  3. ncbi Mutations causing neurodegenerative tauopathies
    Michel Goedert
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Biochim Biophys Acta 1739:240-50. 2005
  4. pmc Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy
    Patrice Delobel
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 OQH, UK
    Am J Pathol 172:123-31. 2008
  5. pmc Regulation of tau pathology by the microglial fractalkine receptor
    Kiran Bhaskar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neuron 68:19-31. 2010
  6. pmc AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies
    Valérie Vingtdeux
    Litwin Zucker Research Center for the Study of Alzheimer s Disease, The Feinstein Institute for Medical Research, North Shore LIJ, 350 Community Drive, Manhasset, NY 11030, USA
    Acta Neuropathol 121:337-49. 2011
  7. ncbi Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies
    R De Silva
    Reta Lila Weston Institute of Neurological Studies, University College London, and Department of Molecular Neuroscience and Neuropathology, Institute of Neurology, UK
    Neuropathol Appl Neurobiol 29:288-302. 2003
  8. pmc Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy
    Veronique Schaeffer
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK
    Brain 135:2169-77. 2012
  9. doi Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability
    Laura Gasparini
    Cambridge Centre for Brain Repair, The University of Cambridge, Robinson Way, Forvie Site, Cambridge CB2 0PY, UK
    Neurobiol Aging 32:419-33. 2011
  10. pmc Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies
    Kunihiro Uryu
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Neuropathol Exp Neurol 67:555-64. 2008

Detail Information

Publications278 found, 100 shown here

  1. doi Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
    Diane P Hanger
    MRC Centre for Neurodegeneration Research, King s College London, Institute of Psychiatry, De Crespigny Park, London, SE5 8AF, UK
    Trends Mol Med 15:112-9. 2009
    ..tau is integral to the pathogenesis of Alzheimer's disease (AD), as well as several related disorders, termed tauopathies, in which tau is deposited in affected brain regions...
  2. ncbi The role of tau (MAPT) in frontotemporal dementia and related tauopathies
    R Rademakers
    Department of Molecular Genetics, Neurogenetics Group, Flanders Interuniversity Institute for Biotechnology, University of Antwerp, Antwerpen, Belgium
    Hum Mutat 24:277-95. 2004
    ..In addition, the role of tau as a genetic susceptibility factor is discussed, together with the genetic evidence for additional causal genes for tau-positive as well as tau-negative dementia...
  3. ncbi Mutations causing neurodegenerative tauopathies
    Michel Goedert
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Biochim Biophys Acta 1739:240-50. 2005
    ..of experimental animal models that reproduce the essential molecular and cellular features of the human tauopathies, including the formation of abundant filaments made of hyperphosphorylated tau protein and nerve cell ..
  4. pmc Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy
    Patrice Delobel
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 OQH, UK
    Am J Pathol 172:123-31. 2008
    ..and may be necessary for the assembly of tau into filaments in Alzheimer's disease and other tauopathies. Here we have investigated the time course of the appearance of phosphorylated and truncated tau in the brain ..
  5. pmc Regulation of tau pathology by the microglial fractalkine receptor
    Kiran Bhaskar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neuron 68:19-31. 2010
    ..the hyperphosphorylated microtubule-associated protein tau (MAPT) are an invariant neuropathological feature of tauopathies. Here, we show that microglial neuroinflammation promotes MAPT phosphorylation and aggregation...
  6. pmc AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies
    Valérie Vingtdeux
    Litwin Zucker Research Center for the Study of Alzheimer s Disease, The Feinstein Institute for Medical Research, North Shore LIJ, 350 Community Drive, Manhasset, NY 11030, USA
    Acta Neuropathol 121:337-49. 2011
    b>Tauopathies represent a class of neurodegenerative disorders characterized by abnormal tau phosphorylation and aggregation into neuronal paired helical filaments (PHFs) and neurofibrillary tangles...
  7. ncbi Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies
    R De Silva
    Reta Lila Weston Institute of Neurological Studies, University College London, and Department of Molecular Neuroscience and Neuropathology, Institute of Neurology, UK
    Neuropathol Appl Neurobiol 29:288-302. 2003
    ..containing fibrillar aggregates of hyperphosphorylated tau protein are a characteristic feature in the tauopathies, which include Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17),..
  8. pmc Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy
    Veronique Schaeffer
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK
    Brain 135:2169-77. 2012
    The accumulation of insoluble proteins is a pathological hallmark of several neurodegenerative disorders. Tauopathies are caused by the dysfunction and aggregation of tau protein and an impairment of cellular protein degradation pathways ..
  9. doi Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability
    Laura Gasparini
    Cambridge Centre for Brain Repair, The University of Cambridge, Robinson Way, Forvie Site, Cambridge CB2 0PY, UK
    Neurobiol Aging 32:419-33. 2011
    Tau inclusions play a key role in the pathogenesis of tauopathies. Altered tau levels have been detected in retina and optic nerve of patients with glaucoma, suggesting the possibility of shared pathogenic mechanisms with tauopathies...
  10. pmc Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies
    Kunihiro Uryu
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Neuropathol Exp Neurol 67:555-64. 2008
    ..These findings provide further insight into the burden and clinical significance of TDP-43 pathology in disorders other than FTLD-U and amyotrophic lateral sclerosis...
  11. ncbi Comparison of family histories in FTLD subtypes and related tauopathies
    J S Goldman
    Memory and Aging Center, University of California, San Francisco, CA 94117, USA
    Neurology 65:1817-9. 2005
    ..FTD/ALS was the most and SD the least heritable subtype. FTLD syndromes appear to have different etiologies and recurrence risks...
  12. ncbi Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L)
    Martin Ramsden
    Department of Neurology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Neurosci 25:10637-47. 2005
    ..Collectively, these data describe a novel transgenic mouse that closely mimics human tauopathy and may represent an important model for the future study of tau-related neurodegenerative disease...
  13. ncbi Tau-mediated neurodegeneration in Alzheimer's disease and related disorders
    Carlo Ballatore
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104 4283, USA
    Nat Rev Neurosci 8:663-72. 2007
    ..our understanding of the mechanisms of tau-mediated neurodegeneration in Alzheimer's disease (AD) and related tauopathies, which are characterized by prominent CNS accumulations of fibrillar tau inclusions, are rapidly moving this ..
  14. pmc Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies
    David J Irwin
    Centre for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Alzheimer s Disease Core Centre, Institute on Ageing, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6021, USA
    Brain 135:807-18. 2012
    ..component of neurofibrillary inclusions characteristic of Alzheimer's disease and related neurodegenerative tauopathies. When tau fibrillizes, it undergoes abnormal post-translational modifications resulting in decreased solubility ..
  15. ncbi Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice
    Dick Terwel
    Experimental Genetics Group, Department of Human Genetics, KU Leuven, B 3000 Leuven, Belgium
    J Biol Chem 280:3963-73. 2005
    ..phosphorylation regulates binding to microtubules and, when disturbed by aging or mutations, results in diverse tauopathies and in neurodegeneration...
  16. ncbi Tau pathology in Alzheimer disease and other tauopathies
    Khalid Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314 6399, USA
    Biochim Biophys Acta 1739:198-210. 2005
    ..It is this pathology which is characteristic of Alzheimer disease (AD) and other tauopathies. To date, the most established and the most compelling cause of dysfunctional tau in AD and other tauopathies ..
  17. ncbi The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts
    Amanda J Myers
    Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892 3707, USA
    Neurobiol Dis 25:561-70. 2007
    ..We discuss these findings both in terms of the problems facing the dissection of the etiologies of complex traits and the pathogenesis of the tauopathies.
  18. pmc Tau in Alzheimer disease and related tauopathies
    K Iqbal
    Department of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, New York 10314 6399, USA
    Curr Alzheimer Res 7:656-64. 2010
    ..Inhibition of abnormal hyperphosphorylation of tau offers a promising therapeutic target for AD and related tauopathies.
  19. doi A new link to mitochondrial impairment in tauopathies
    Kathrin L Schulz
    Department of Pharmacology, ZAFES, Biocenter, University of Frankfurt, 60438 Frankfurt, Germany
    Mol Neurobiol 46:205-16. 2012
    b>Tauopathies like the "frontotemporal dementia with Parkinsonism linked to chromosome 17" (FTDP-17) are characterized by an aberrant accumulation of intracellular neurofibrillary tangles composed of hyperphosphorylated tau...
  20. pmc Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation
    Wen Lang Lin
    Mayo Clinic, Jacksonville, Florida, USA
    Am J Pathol 162:213-8. 2003
    ..Given similarities of the lesions in the mice to human neuronal and glial inclusions, these transgenic mice appear to be a valuable model to study pathogenesis of the neurodegenerative tauopathies.
  21. ncbi Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects
    Natalia Shiryaev
    The Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Pharm Des 17:2603-12. 2011
    ..These studies associate neuroprotection in vivo and in vitro and provide a broad base for future drug development based on NAP and D-SAL against multiple neurodegenerative conditions...
  22. pmc MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies
    Daniah Trabzuni
    Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Hum Mol Genet 21:4094-103. 2012
    ....
  23. pmc Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies
    Tara Vanderweyde
    Department of Pharmacology, Boston University School of Medicine, Boston, Massachusetts 02118 2526, USA
    J Neurosci 32:8270-83. 2012
    ....
  24. ncbi A novel organotypic tauopathy model on a new microcavity chip for bioelectronic label-free and real time monitoring
    Dana Krinke
    Centre for Biotechnology and Biomedicine BBZ, University of Leipzig, Division of Molecular Biological Biochemical Processing Technology, Deutscher Platz 5, 04103 Leipzig, Germany
    Biosens Bioelectron 26:162-8. 2010
    ..Moreover, we were able to detect and quantify distinct, AD-related effects triggered by tau-mutant (P301L) expression and hyperphosphorylation in our organotypic 3D-cultures with the help of impedance spectroscopy...
  25. doi An okadaic acid-induced model of tauopathy and cognitive deficiency
    Zhang Zhang
    Deptment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
    Brain Res 1359:233-46. 2010
    ....
  26. pmc Transgenic Drosophila models of Alzheimer's disease and tauopathies
    Kanae Iijima-Ando
    Laboratory of Neurogenetics and Pathobiology, Department of Biochemistry and Molecular Biology, Farber Institute for Neurosciences, Thomas Jefferson University, 900 Walnut Street, JHN410, Philadelphia, PA, 19107, USA
    Brain Struct Funct 214:245-62. 2010
    ..dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and other related diseases, so called tauopathies. Although most cases are sporadic, genes associated with familial AD and FTDP-17 have been identified, which ..
  27. ncbi Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies
    Hanae Nakashima
    Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, 700 8558, Okayama, Japan
    Acta Neuropathol 110:547-56. 2005
    ..Thus, lithium could have therapeutic benefit in neurodegenerative tauopathies by reducing tau hyperphosphorylation...
  28. pmc Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain
    Allal Boutajangout
    Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA
    J Neurochem 118:658-67. 2011
    Targeting hyperphosphorylated tau by immunotherapy is emerging as a promising approach to treat tauopathies such as Alzheimer's disease and frontotemporal dementia...
  29. ncbi Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau
    Wen Lang Lin
    Mayo Clinic, Jacksonville, Florida 32224, USA
    J Neurocytol 32:1091-105. 2003
    ..The other type resembled ballooned neurons seen in some human tauopathies. The nucleus was peripherally placed, but normal appearing...
  30. ncbi Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation
    Jose A Rodriguez-Navarro
    Department of Neurobiology, Hospital Ramon y Cajal, and CIBERned Madrid, Spain
    Neurobiol Dis 39:423-38. 2010
    b>Tauopathies are neurodegenerative diseases, sporadic or familial, mainly characterized by dementia and parkinsonism associated to atrophy of the frontotemporal cortex and the basal ganglia, with deposition of abnormal tau in brain...
  31. doi Upper airway dysfunction of Tau-P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei
    Mathias Dutschmann
    Institute of Membrane and Systems Biology, University of Leeds, Leeds LS2 9JT, United Kingdom
    J Neurosci 30:1810-21. 2010
    ..Some primary tauopathies are linked to mutations in the MAPT gene coding for protein tau, but most are sporadic with unknown causes...
  32. pmc Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model
    Leora M Fox
    Massachusetts General Hospital Harvard Medical School, MassGeneral Institute for Neurodegenerative Disease, Charlestown, 02129, USA
    J Neuropathol Exp Neurol 70:588-95. 2011
    Neurofibrillary tangles are a feature of Alzheimer disease and other tauopathies, and although they are generally believed to be markers of neuronal pathology, there is little evidence evaluating whether tangles directly impact neuronal ..
  33. ncbi Tau pathology and future therapeutics
    I Gozes
    Laboratory for Molecular Neuroendocrinology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    Curr Alzheimer Res 7:685-96. 2010
    ....
  34. doi Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression
    Tadanori Hamano
    Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL, USA
    Eur J Neurosci 27:1119-30. 2008
    ..pathological hallmark shared by Alzheimer's disease and other neurodegenerative disorders known collectively as tauopathies. To model how tau fibrillogenesis evolves in tauopathies, we previously established transfectant M1C cultures ..
  35. pmc Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
    Kurt R Brunden
    Center for Neurodegenerative Disease Research, Institute on Aging, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104 4283, USA
    Nat Rev Drug Discov 8:783-93. 2009
    ..of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathological agent...
  36. doi Alzheimer's disease: old problem, new views from transgenic and viral models
    Tomasz Jaworski
    Experimental Genetics Group, LEGTEGG, Dept Human Genetics, KULeuven Campus Gasthuisberg ON1 06 602, Herestraat 49, B 3000 Leuven, Belgium
    Biochim Biophys Acta 1802:808-18. 2010
    ..We focus on specific aspects of single and multiple transgenic mouse models for Alzheimer's disease and for tauopathies, rather than providing an exhaustive list of all available models...
  37. pmc Is tau ready for admission to the prion club?
    Garth F Hall
    Department of Biological Sciences, University of Massachusetts Lowell, Lowell, MA, USA
    Prion 6:223-33. 2012
    ....
  38. doi Raphé tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease
    Clement Menuet
    Maturation, Plasticity, Physiology and Pathology of Respiration MP3 Respiration, Unité Mixte de Recherche 6231, Centre National de la Recherche Scientifique, Universite de la Mediterranee, Universite Paul Cezanne, Faculté Saint Jérôme Service 362, 13397 Marseille Cedex 20, France
    Respir Physiol Neurobiol 178:290-303. 2011
    b>Tauopathies, including Alzheimer's disease are the most frequent neurodegenerative disorders in elderly people...
  39. pmc Tau isoform composition influences rate and extent of filament formation
    Qi Zhong
    Department of Molecular and Cellular Biochemistry, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    J Biol Chem 287:20711-9. 2012
    ..In general, aggregation propensity correlated with genetic risk reported for multiple tauopathies, implicating aggregation as one candidate mechanism rationalizing the correlation between Tau expression ..
  40. pmc Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy
    Kurt R Brunden
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 30:13861-6. 2010
    ..Accordingly, a possible therapeutic strategy for AD and related "tauopathies" is treatment with a MT-stabilizing anti-cancer drug such as paclitaxel...
  41. doi Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein
    Sébastien Feuillette
    INSERM U614, Rouen Institute for Medical Research, Faculty of Medicine, University of Rouen, Rouen Cedex, France
    J Neurochem 113:895-903. 2010
    Tau is a neuronal microtubule-associated protein involved in microtubules assembly and stabilization. Tauopathies, including Alzheimer's disease and fronto-temporal dementia with parkinsonism linked to chromosome 17, are a group of ..
  42. pmc Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies
    C Ballatore
    Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th St, Philadelphia, PA 19104 6323, USA
    Curr Top Med Chem 11:317-30. 2011
    ..and unresolved issues surrounding the development of novel therapeutics for the treatment of neurodegenerative tauopathies, which are based on (A) MT-stabilizing agents to compensate for the loss of normal tau function, and (B) small ..
  43. ncbi The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy
    Günter U Höglinger
    INSERM U679, Hopital de la Salpetriere, Paris, France
    J Neurochem 95:930-9. 2005
    ..Our data suggest that chronic respiratory chain dysfunction might trigger a form of neurodegeneration in which accumulation of hyperphosphorylated tau protein predominates over deposits of alpha-synuclein...
  44. pmc Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice
    Dick Terwel
    Experimental Genetics Group, Department Human Genetics, Katholieke Universiteit Leuven Campus Gasthuisberg ON1 06 602, B 3000 Leuven, Belgium
    Am J Pathol 172:786-98. 2008
    ..The data indicate that amyloid induces tauopathy through activation of GSK-3 and suggest a role for the kinase in maintaining the functional integrity of adult neurons...
  45. doi Tau alternative splicing in familial and sporadic tauopathies
    Michael Niblock
    Department of Clinical Neuroscience, Institute of Psychiatry, King s College London, London, UK
    Biochem Soc Trans 40:677-80. 2012
    ..Tau alternative splicing could represent a target for therapeutic intervention to delay the progression of pathology in familial as well as sporadic tauopathies.
  46. ncbi Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1
    Ji Wu Wang
    Department of Pathology, Stanford University School of Medicine, and Geriatric Research, Education, and Clinical Center Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    J Neurosci 27:574-81. 2007
    ..These results reveal a new function for the tumor suppressor protein LKB1 in a signaling cascade through which the phosphorylation and function of tau is regulated by diverse signals under physiological and pathological conditions...
  47. pmc Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy
    Michiyo Iba
    Center for Neurodegenerative Disease Research, Institute on Aging, Department of Pathology and Laboratory, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Neurosci 33:1024-37. 2013
    b>Tauopathies, including Alzheimer's disease (AD) and frontotemporal lobar degeneration with tau pathologies, are neurodegenerative diseases characterized by neurofibrillary tangles (NFTs) comprising filamentous tau protein...
  48. doi Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains
    Sébastien Feuillette
    INSERM U614, Institute for Biomedical Research, Faculty of Medicine, University of Rouen, Rouen, France
    Brain Res 1345:182-9. 2010
    b>Tauopathies, including Alzheimer's disease (AD), fronto-temporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Pick's disease and progressive supranuclear palsy, are neurodegenerative disorders neuropathologically ..
  49. doi Pathogenesis of the tauopathies
    Michel Goedert
    MRC Laboratory of Molecular Biology, Hills Road, Cambridge, CB2 0QH, UK
    J Mol Neurosci 45:425-31. 2011
    ..However, most tauopathies are not inherited in a dominant manner...
  50. pmc Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies
    Tomas L Falzone
    Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Hum Mol Genet 19:4399-408. 2010
    ..hyperphosphorylation and aggregation of the microtubule-associated protein tau defines neurodegenerative tauopathies. Destabilization of microtubules by loss of tau function and filament formation by toxic gain of function are ..
  51. pmc Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
    A C Ludolph
    Department of Neurology, University of Ulm, Ulm, Germany
    Eur J Neurol 16:297-309. 2009
    b>Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system...
  52. ncbi Tauopathies
    F Hernandez
    Centro de Biologia Molecular Severo Ochoa, CSIC UAM, Fac Ciencias, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain
    Cell Mol Life Sci 64:2219-33. 2007
    ..of its isoforms could provoke pathological effects resulting in the appearance of neuronal disorders known as tauopathies. The purpose of this work is to review the possible mechanisms for tau alterations that could lead to the onset ..
  53. ncbi Tau and tauopathies
    M Robert
    Department of Neurology, Medical College, Trivandrum, Kerala, India
    Neurol India 55:11-6. 2007
    ..neuronal, oligodendroglial or astrocytic filamentous tau inclusions are now grouped under the common rubric of tauopathies. The discovery of mutations in the tau gene, located on Chromosome 17 and its relationship to frontotemporal ..
  54. ncbi CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival
    Hideki Shimura
    Department of Neurology, Harvard Medical School and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 279:4869-76. 2004
    ..CHIP could rescue phosphorylated tau-induced cell death, and therefore the CHIP-Hsc70 complex may provide a new therapeutic target for the tauopathies.
  55. ncbi Progressive neurodegeneration in C. elegans model of tauopathy
    Tomohiro Miyasaka
    Department of Neuropathology, Faculty of Medicine, University of Tokyo, 7 3 1 Hongo, Tokyo 113 0033, Japan
    Neurobiol Dis 20:372-83. 2005
    ..Expression of GSK3 brought about slight deterioration in the touch response, while expression of HSP70 led to some improvement...
  56. ncbi Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease
    Manuela Neumann
    Institute of Neuropathology, Ludwig Maximilians University of Munich, Munich, Germany
    Acta Neuropathol 107:489-96. 2004
    ..antibodies against DJ-1, we have performed a comprehensive investigation of DJ-1 in alpha-synucleinopathies and tauopathies. DJ-1 was abundantly expressed in reactive astrocytes of patients with neurodegenerative diseases...
  57. ncbi Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease
    Masashi Kitazawa
    Department of Neurobiology and Behavior, University of California Irvine, California 92697 4545, USA
    J Neurosci 25:8843-53. 2005
    ..Therefore, this study clearly demonstrates that microglial activation exacerbates key neuropathological features such as tangle formation...
  58. pmc Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy
    Brian C Kraemer
    Geriatrics Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108 1597, USA
    Proc Natl Acad Sci U S A 100:9980-5. 2003
    ..soluble and insoluble tau is phosphorylated at many of the sites hyperphosphorylated in FTDP-17, AD, and other tauopathies. Substantial neurodegeneration, seen as bulges and gaps in nerve cords followed by loss of neurons, occurs ..
  59. pmc Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases
    Nicholas M Kanaan
    Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Neurosci 31:9858-68. 2011
    ..tau (a microtubule-associated protein) represent pathological hallmarks of Alzheimer's disease (AD) and other tauopathies. While axonal transport dysfunction is thought to represent a primary pathogenic factor in AD and other ..
  60. ncbi Disentangling the role of the tau gene locus in sporadic tauopathies
    J Vandrovcova
    Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, 1 Wakefield Street, London, WC1N 1PJ, UK
    Curr Alzheimer Res 7:726-34. 2010
    ..neurofibrillary tangles that define the broad class of late-onset neurodegenerative disorders called the tauopathies. Mutations in the tau gene (MAPT) causing familial frontotemporal dementia with parkinsonism linked to ..
  61. ncbi Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration
    Makoto Higuchi
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neuron 35:433-46. 2002
    ..including corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP), are neurodegenerative tauopathies characterized by widespread CNS neuronal and glial tau pathologies, but there are no tau transgenic (Tg) mice ..
  62. ncbi Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain
    Koichi Wakabayashi
    Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
    Acta Neuropathol 120:1-12. 2010
    ..Further elucidation and characterization of PNS lesions will have implications for intravital biopsy diagnosis in neurodegenerative proteinopathy, particularly in Parkinson's disease...
  63. doi 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy
    Astrid Sydow
    Max Planck Unit for Structural Molecular Biology, Hamburg, Germany
    Neurodegener Dis 7:28-31. 2010
    ..However, since the mice contain both endogenous wild-type mouse tau and exogenous human mutant tau, the relative contribution of these components to the aggregates has been a matter of debate...
  64. pmc Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro
    Dong Han
    Bloomfield Center for Research in Aging, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital
    J Biol Chem 284:13422-33. 2009
    In Alzheimer disease (AD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and other tauopathies, tau accumulates and forms paired helical filaments (PHFs) in the brain...
  65. pmc Detection of filamentous tau inclusions by the fluorescent Congo red derivative FSB [(trans,trans)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene]
    Ana Velasco
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 0QH, UK
    FEBS Lett 582:901-6. 2008
    ..More importantly, tau inclusions in the spinal cord of human P301S tau transgenic mice were labelled following a single intravenous injection of FSB. These findings indicate that FSB can be used to detect filamentous tau in vivo...
  66. doi Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis
    Guofeng Yang
    Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing 100853, China
    Neurol Res 30:613-22. 2008
    To identify differentially expressed proteins between tauopathies cases and controls and to explore molecular mechanisms of tauopathies.
  67. ncbi Biochemistry and molecular biology of tauopathies
    Masato Hasegawa
    Department of Molecular Neurobiology, Tokyo Institute of Psychiatry, Tokyo Metropolitan Organization for Medical Research, Tokyo, Japan
    Neuropathology 26:484-90. 2006
    Filamentous tau deposits in neurons or glial cells are the hallmark lesions of neurodegenerative tauopathies, such as Alzheimer's disease, Pick's disease, corticobasal degeneration and progressive supranuclear palsy...
  68. ncbi Effects of alpha-tocopherol on an animal model of tauopathies
    Hanae Nakashima
    Department of Neuropsychiatry, Okayama University Graduate School of Medicine and Dentistry, Shikata cho, 700 8558, Japan
    Free Radic Biol Med 37:176-86. 2004
    ..We overexpressed the smallest human tau isoform (T44) in the mouse CNS to model tauopathies. These tau Tg mice acquire age-dependent CNS pathologies, including insoluble, hyperphosphorylated tau and ..
  69. doi Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies
    Norbert Zilka
    Centre of Excellence for Alzheimer s Disease and Related Disorders, Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska 9, 84510 Bratislava, Slovak Republic
    Acta Neuropathol 118:71-86. 2009
    Human tauopathies represent a heterogeneous group of neurodegenerative disorders such as Alzheimer's disease (AD) that are characterized by the presence of intracellular accumulations of abnormal filaments of protein tau...
  70. ncbi Tauopathies: one disease or many?
    Manon Bouchard
    Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
    Can J Neurol Sci 38:547-56. 2011
    b>Tauopathies are a group of disorders that have in common abnormal accumulation of tau protein in the brain...
  71. ncbi Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7
    G G Kovacs
    Institute of Neurology, Medical University of Vienna, Vienna, Austria
    Clin Neuropathol 30:3-10. 2011
    ..Our observation of an apparently familial disorder with a novel neuropathological phenotype suggests a possible pathogenic role of this MAPT gene variation, which might be different from mutations affecting the microtubule binding...
  72. doi The power and richness of modelling tauopathies in Drosophila
    Katerina Papanikolopoulou
    Institute of Cellular and Developmental Biology, Biomedical Sciences Research Centre Alexander Fleming, Vari 16672, Greece
    Mol Neurobiol 44:122-33. 2011
    b>Tauopathies are a group of neurodegenerative disorders characterised by altered levels of phosphorylation or mutations in the neuronal microtubule protein Tau...
  73. ncbi O-GlcNAc modification and the tauopathies: insights from chemical biology
    Scott A Yuzwa
    Department of Molecular Biology and Biochemistry, Simon Fraser University, 8888 University Dr, Burnaby, BC, V5A 1S6, Canada
    Curr Alzheimer Res 6:451-4. 2009
    ..of the microtubule-associated protein tau into paired-helical filaments is the defining characteristic of the tauopathies. It has become apparent that the hyperphosphorylation of tau likely plays a role in the aggregation process and ..
  74. ncbi Tau-positive fine granules in the cerebral white matter: a novel finding among the tauopathies exclusive to parkinsonism-dementia complex of Guam
    Mineo Yamazaki
    Department of Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Fuchu shi, Tokyo, Japan
    J Neuropathol Exp Neurol 64:839-46. 2005
    ..The TFGs were hyperphosphorylated tau-positive structures that may be formed by a different mechanism from that used to produce cortical NFTs...
  75. ncbi Tauopathies: recent insights into old diseases
    Andre Delacourte
    Inserm Unit 815, 1, Place de Verdun, 59045 Lille Cedex France
    Folia Neuropathol 43:244-57. 2005
    ..Together, these observations have generated the concept of tauopathies. Indeed, each tauopathy is defined by a combination of clinical, neuropathological, biochemical and genetic ..
  76. pmc The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies
    Kurt R Brunden
    Center for Neurodegenerative Disease Research and Institute on Aging, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
    Pharmacol Res 63:341-51. 2011
    ..Several neurodegenerative disorders referred to as tauopathies, including Alzheimer's disease and certain types of frontotemporal lobar degeneration, are characterized by the ..
  77. ncbi Transgenic animal models of tauopathies
    Virginia M Y Lee
    University of Pennsylvania School of Medicine, Pathology, 3600 Spruce Street, HUP, 3rd Floor Maloney Building 1914104 4283, Philadelphia, PA, USA
    Biochim Biophys Acta 1739:251-9. 2005
    b>Tauopathies are a group of neurodegenerative disorders that include Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and other related diseases with prominent tau pathology...
  78. ncbi Tau phosphorylation and aggregation as a therapeutic target in tauopathies
    Nahuai Badiola
    Servicio de Neurologia, Hospital de Sant Pau, Universidad Autonoma de Barcelona, Barcelona, Spain
    CNS Neurol Disord Drug Targets 9:727-40. 2010
    b>Tauopathies are neurodegenerative diseases characterized by insoluble hyperphosphorylated deposits of the microtubule-associated protein tau in the central nervous system...
  79. pmc Knock-out and transgenic mouse models of tauopathies
    Franziska Denk
    The Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom
    Neurobiol Aging 30:1-13. 2009
    b>Tauopathies, characterized by the dysfunction and aggregation of the microtubule-associated protein tau (MAPT), represent some of the most devastating neurodegenerative disorders afflicting the elderly, including Alzheimer's disease and ..
  80. pmc Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
    Giulio Maria Pasinetti
    Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Neurochem 114:1557-68. 2010
    ..palsy (PSP), corticobasal degeneration and Alzheimer's disease among others, collectively referred to as tauopathies - are characterized by progressive, age-dependent intracellular formations of misfolded protein aggregates that ..
  81. ncbi A comparison of the neuronal dysfunction caused by Drosophila tau and human tau in a Drosophila model of tauopathies
    Kiren K Ubhi
    Department of Neuroscience, University of Southampton, School of Biological Sciences, Bassett Crescent East, Southampton, SO16 7PX, UK
    Invert Neurosci 7:165-71. 2007
    ..and aggregation of tau into tangles is a feature of disorders such as Alzheimer's disease and other Tauopathies. To model these disorders in Drosophila melanogaster, human tau has been over-expressed and a variety of ..
  82. pmc Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies
    Jianhua Zhou
    Department of Medicine, Program in Neuroscience, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA
    BMC Neurosci 9:S10. 2008
    Tau aggregation is one of the major features in Alzheimer's disease and in several other tauopathies, including frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), and progressive supranuclear palsy (PSP)...
  83. ncbi Neuroprotective properties of valproate: potential benefit for AD and tauopathies
    Rebekah Loy
    Department of Neurology, Program in Neurobehavioral Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
    J Mol Neurosci 19:303-7. 2002
    ..Together, these studies will provide important tests of the hypothesis that valproate, either through inhibition of tau phosphorylation or some other mechanism, is a useful therapeutic agent to modify disease progression in AD...
  84. ncbi A minimal length between tau exon 10 and 11 is required for correct splicing of exon 10
    Qingming Yu
    Department of Medicine and Program in Neuroscience, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    J Neurochem 90:164-72. 2004
    ..tau mRNA cause frontotemporal dementia with parkinsonism, associated with chromosome 17 (FTDP-17), and other tauopathies. This suggests that the ratio of exon 10 inclusion to exclusion in adult brain is one of the factors to ..
  85. ncbi Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies
    Matthew R Reynolds
    Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Neurosci 26:10636-45. 2006
    The neurodegenerative tauopathies are a clinically diverse group of diseases typified by the pathological self-assembly of the microtubule-associated tau protein...
  86. pmc Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies
    George Perry
    Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA
    Neurodegener Dis 5:222-4. 2008
    ..Mutations in leucine-rich repeat kinase 2 (LRRK2) are thus far the most frequent genetic cause associated with autosomal dominant and idiopathic Parkinson's disease...
  87. ncbi Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies
    Mari Yoshida
    Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan
    Neuropathology 26:457-70. 2006
    ..fibrillary aggregates of abnormally hyperphosphorylated tau protein are characteristic features in sporadic tauopathies. In the first part of this paper we outline the morphological features of some major sporadic tauopathies...
  88. ncbi Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals
    Feng Chen
    Division of Psychiatry Research, University of Zurich, August Forel Str 1, 8008 Zurich, Switzerland
    Curr Drug Targets 5:503-15. 2004
    ..of scant or no beta-amyloid plaques characterizes additional neurodegenerative disorders collectively called tauopathies. In the course of plaque and NFT formation, the major proteinaceous components of these lesions undergo post-..
  89. doi Proteasome subunit proteins and neuropathology in tauopathies and synucleinopathies: Consequences for proteomic analyses
    Mohamed Zouambia
    Faculte des Sciences Biologiques, Université des Sciences et des Technologies Houari Boumediène, Algiers, Algeria
    Proteomics 8:1221-36. 2008
    ..In other tauopathies (Pick's disease, frontotemporal dementia, progressive supranuclear palsy and argyrophilic grain disease), ..
  90. ncbi Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies
    Markus Tolnay
    Institute of Pathology, Department of Neuropathology, University Hospital Basel, Basel, Switzerland
    Neuropathology 24:269-83. 2004
    ....
  91. pmc Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1
    Patrice Delobel
    Medical Research Council Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, UK
    Am J Pathol 168:878-87. 2006
    ..and cause the hyperphosphorylation and filament formation of tau protein in Alzheimer's disease and other tauopathies. Here we have analyzed the expression and/or activation of proteins involved in cell-cycle progression in the ..
  92. ncbi RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies
    J M Gallo
    MRC Centre for Neurodegeneration Research, King s College London, Institute of Psychiatry, Box P037, De Crespigny Park, London, SE5 8AF, UK
    Cell Mol Life Sci 64:1701-14. 2007
    b>Tauopathies are a group of neurodegenerative diseases characterised by intracellular deposits of the microtubule-associated protein tau. The most typical example of a tauopathy is Alzheimer's disease...
  93. doi Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy
    Norbert Zilka
    Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak Republic
    J Neuroimmunol 209:16-25. 2009
    It has been hypothesized that misfolded tau protein could be a mediator of the inflammatory response in human tauopathies. Here we show that neurodegenerative lesions caused by human truncated tau promote inflammatory response manifested ..
  94. ncbi Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains
    I Ferrer
    Institut de Neuropatologia, Servei d Anatomia Patològica, Hospital Princeps d Espanya, Spain
    Acta Neuropathol 104:658-64. 2002
    ..in astrocytes suggests different kinase equipment and activation in comparing neurons and astrocytes in tauopathies. Pick bodies in PiD and grains in AGD are weakly, or not all, immunostained in tissue samples with long post-..
  95. ncbi The role of tau phosphorylation and cleavage in neuronal cell death
    Wanjoo Chun
    Department of Psychiatry, School of Medicine, University of Alabama at Birmingham, 1061 Sparks Center, 1720 7th Avenue South, Birmingham, AL 35294 0017, USA
    Front Biosci 12:733-56. 2007
    ..deposits found in Alzheimer's disease (AD) brain and also in a family of neurodegenerative diseases called 'tauopathies', where tau pathology is the primary, defining characteristic with little or no amyloid-beta (Abeta) pathology...
  96. pmc Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies
    Wenjie Luo
    Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University and Fisher Foundation for Alzheimer s Disease, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 104:9511-6. 2007
    ..b>Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, ..
  97. ncbi Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L
    Atsushi Sasaki
    Department of Human Pathology, Gunma University Graduate School of Medicine, Gunma, Japan
    Brain Res 1214:159-68. 2008
    ..to phosphorylated tau accumulation and the characteristics of microglial activation in brain lesions of human tauopathies in comparison to mutant tau transgenic (TG) mice...
  98. ncbi Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration
    Keith A Josephs
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Neurol 61:1579-84. 2004
    To determine if apolipoprotein E epsilon 4 influences the frequency of Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration and to determine if the frequency of Alzheimer-type pathologic ..
  99. doi Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies
    Jozef Hanes
    Axon Neuroscience GmbH, Rennweg, Vienna, Austria
    J Neurochem 108:1167-76. 2009
    ..containing either three (3R) or four (4R) repeat domains, all of which participate in the pathogenesis of human tauopathies. To investigate the role of tau protein in the disease, transgenic rat models have been created...
  100. ncbi Clinicopathological features of the tauopathies
    B Murray
    Department of Neurology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland
    Biochem Soc Trans 33:595-9. 2005
    ..clinicopathological diversity of the tau-related disorders with specific reference to three of the most common tauopathies, frontotemporal dementia (familial and sporadic), progressive supranuclear palsy and corticobasal degeneration.
  101. ncbi Pinning down phosphorylated tau and tauopathies
    Jormay Lim
    Cancer Biology Program Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, NRB 1030K, Boston, MA 02215, USA
    Biochim Biophys Acta 1739:311-22. 2005
    ..Thus, Pin1 is pivotal in maintaining normal neuronal function and preventing age-dependent neurodegeneration. This could represent a promising interventive target to prevent neurodegenerative diseases...

Research Grants91

  1. TDP-43 acetylation as a pathogenic modification in ALS &related proteinopathies
    TODD JONATHAN COHEN; Fiscal Year: 2012
    ..that acetylation of the tau protein promotes tangle formation in Alzheimer's disease and related tauopathies (Nat Commun. 2011~2:252)...
  2. In vivo imaging agents targeting Tau aggregates
    HANK KUNG; Fiscal Year: 2007
    ..Alzheimer's disease and other Tauopathies are neurodegenerative diseases of the brain...
  3. ROLE OF HSP 110 IN TAUOPATHY
    NAHID MIVECHI; Fiscal Year: 2009
    ..The neuropathological hallmarks of AD and other tauopathies include accumulation of senile plaques and/or neurofibrillary tangles (NFTs) that causes neurons to degenerate...
  4. CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN AD
    Mony J de Leon; Fiscal Year: 2010
    ..This project will test the hypothesis that validated biological markers for neurofibrillary tangle and amyloid plaque pathology contribute to FDG-PET in predicting future cognitive decline in cognitively normal subjects. ..
  5. CLINICAL CORRELATES OF LONGITUDINAL PET CHANGES IN AD
    Mony de Leon; Fiscal Year: 2009
    ..This project will test the hypothesis that validated biological markers for neurofibrillary tangle and amyloid plaque pathology contribute to FDG-PET in predicting future cognitive decline in cognitively normal subjects. ..
  6. Regulatory functions of alpha 1-antichymotrypsin in inflammation and Alzheimer's
    Jaya Padmanabhan; Fiscal Year: 2010
    ..the mechanisms involved in ACT's role in development of tau pathologies that are associated with AD or tauopathies, and will identify novel targets for development of therapies towards AD...
  7. The role of a novel tau-associated protein in neurodegeneration
    Irving Vega; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Tauopathies are a family of neurodegenerative disorders characterized by the intracellular aggregation of filaments derived from hyperphosphorylated microtubule-associated protein tau...
  8. The role of a novel tau-associated protein in neurodegeneration
    Irving E Vega; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Tauopathies are a family of neurodegenerative disorders characterized by the intracellular aggregation of filaments derived from hyperphosphorylated microtubule-associated protein tau...
  9. Peripheral TGF-beta Pathway Inhibitor Therapy in Alzheimer's Rats
    Terrence Town; Fiscal Year: 2011
    ..If results from our Alzheimer's transgenic rat model establish the importance of this pathway, this could unveil a new therapeutic approach. ..
  10. Colloquium on the Cytoskeleton and Human Disease
    Leslie Wilson; Fiscal Year: 2001
    ..new compounds), 2)microtubule-associated proteins and neurodegenerative disease (Alzheimer's disease and other tauopathies, new concepts and new targets), 3)intermediate filaments and disease (keratin and skin diseases, desmin in ..
  11. BIOLOGY OF CHROMOSOME 17 LINKED DEMENTIA WITH TAUOPATHY
    Jill Murrell; Fiscal Year: 1999
    ..The members of the team are highly experienced investigators in their field of endeavor. ..
  12. BIOLOGY OF CHROMOSOME 17 LINKED DEMENTIA WITH TAUOPATHY
    Jill Murrell; Fiscal Year: 2000
    ..The members of the team are highly experienced investigators in their field of endeavor. ..
  13. TAU ALTERATIONS IN ALZHEIMER'S AND RELATED DEMENTIAS
    Bradley Hyman; Fiscal Year: 2004
    ..the study of neurofibrillary tangles in Alzheimer disease will be compared to parallel studies of non-Alzheimer tauopathies: sporadic Pick disease, progressive supranuclear palsy, and cases of FTDP-17 with known tau mutations...
  14. High throughput tau oligomer assay for drug screening for Alzheimer's disease
    James G Moe; Fiscal Year: 2010
    ..tau oligomers that will be developed during the Phase III program and evaluated in animal models of AD and tauopathies. To attain this result, the high throughput assay will be optimized and transferred to the Michigan High ..
  15. Canonical Wnt Signaling by the Proteolytc Processing of LRP6
    Brandon Beagle; Fiscal Year: 2007
    ..and has been implicated in generating aberrantly hyperphosporylated tau proteins associated with AD and other tauopathies. Hence, identifying the mechanisms and proteins that regulate GSK3 activity will provide pertinent pathological ..
  16. Canonical Wnt Signaling by the Proteolytc Processing of LRP6
    Brandon Beagle; Fiscal Year: 2009
    ..and has been implicated in generating aberrantly hyperphosporylated tau proteins associated with AD and other tauopathies. Hence, identifying the mechanisms and proteins that regulate GSK3 activity will provide pertinent pathological ..
  17. Tau phosphorylation and neurodegeneration
    Alejandra del C Alonso; Fiscal Year: 2009
    ..in vitro results and of different tau phosphorylation sites will provide an explanation of the progression of tauopathies and it will identify new therapeutic targets for neurodegenerative diseases...
  18. Canonical Wnt Signaling by the Proteolytc Processing of LRP6
    BRANDON RICHARD BEAGLE; Fiscal Year: 2010
    ..and has been implicated in generating aberrantly hyperphosporylated tau proteins associated with AD and other tauopathies. Hence, identifying the mechanisms and proteins that regulate GSK3 activity will provide pertinent pathological ..
  19. Four Repeat Tauopathy Neuroimaging Initiative
    Adam L Boxer; Fiscal Year: 2010
    ..Increasingly, clinical trials of such tau therapies are focusing on pure tauopathies, or disorders in which tau is causally- or strongly-linked to the underlying pathology in the absence of other ..
  20. ALPHA-SYNUCLEIN-INDUCED AMYLOIDOSIS
    John Trojanowski; Fiscal Year: 2005
    ..LBVAD), as well as in familial AD and Down's syndrome, while LBs and Lewy neurites have been reported in some tauopathies such as progressive supranuclear palsy (PSP) and Guam amyotrophic lateral sclerosis/parkinsonism dementia ..
  21. Subgroups of Alzheimer Disease
    Khalid Iqbal; Fiscal Year: 2007
    ..tau, a hallmark brain lesion of Alzheimer disease (AD), Down syndrome, frontotemporal dementia, and other tauopathies, and employ this information to identify and diagnose the different subgroups of Alzheimer's disease...
  22. Modeling Human Tauopathies in Drosophila melanogaster
    Gena Heidary; Fiscal Year: 2003
    ..melanogaster to determine the role of the microtubule-associated protein (MAP) tau in the pathogenesis of human tauopathies. The tau protein has been implicated in at least 20 neurodegenerative diseases collectively referred to as ..
  23. PTEN, Cell Cycle and Neurofibrillary Degeneration
    Francesca Fang Liao; Fiscal Year: 2010
    ..Although NFTs are coincident with cell death in several neurodegenerative diseases, known as tauopathies, and most notably in AD, the molecular mechanisms leading to this chronic loss of neuronal cells is still not ..
  24. PTEN, Cell Cycle and Neurofibrillary Degeneration
    Francesca Fang Liao; Fiscal Year: 2009
    ..Although NFTs are coincident with cell death in several neurodegenerative diseases, known as tauopathies, and most notably in AD, the molecular mechanisms leading to this chronic loss of neuronal cells is still not ..
  25. Mechanisms of Tau-Based Neurodegeneration
    Mark Forman; Fiscal Year: 2003
    ..in neurons, astrocytes and oligodendrocytes are the neuropathological hallmark of both sporadic and familial tauopathies. Alzheimer's disease (AD), the most common tauopathy, is characterized by the deposition of numerous Ap-rich ..
  26. Mechanisms of Tau-Based Neurodegeneration
    Mark Forman; Fiscal Year: 2001
    ..in neurons, astrocytes and oligodendrocytes are the neuropathological hallmark of both sporadic and familial tauopathies. Alzheimer's disease (AD), the most common tauopathy, is characterized by the deposition of numerous Ap-rich ..
  27. GENETICS AND MOLECULAR BIOLOGY OF PARKINSONISM
    DENNIS WILLIAM DICKSON; Fiscal Year: 2012
    ..tau is related PD and how tau-directed therapies may translate into novel treatments for PD and parkinsonian tauopathies. The proposed Center will have three projects and four cores with an overarching theme to understand the role ..
  28. Molecular determinants of lamin a accumulation in human aging and disease
    Agnieszka Kalinowski; Fiscal Year: 2010
    ..other pathologies that result from destructive protein-membrane interactions, such as Alzheimer's disease, tauopathies and prion diseases...
  29. MECHANISM AND CONTROL OF BRAIN MICROTUBULE DYNAMICS
    Leslie Wilson; Fiscal Year: 2006
    ..how the tau proteins, which stabilize microtubules and may mis-regulate dynamics in neurodegenerative tauopathies such as Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and the stathmin/SCG10 ..
  30. MECHANISM AND CONTROL OF BRAIN MICROTUBULE DYNAMICS
    Leslie Wilson; Fiscal Year: 2007
    ..how the tau proteins, which stabilize microtubules and may mis-regulate dynamics in neurodegenerative tauopathies such as Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and the stathmin/SCG10 ..
  31. MECHANISM AND CONTROL OF BRAIN MICROTUBULE DYNAMICS
    Leslie Wilson; Fiscal Year: 2009
    ..how the tau proteins, which stabilize microtubules and may mis-regulate dynamics in neurodegenerative tauopathies such as Frontotemporal Dementia with Parkinsonism linked to chromosome 17 (FTDP-17) and the stathmin/SCG10 ..
  32. Temporal Changes in MicroRNA Function During Tau tangle Accumulation
    CATHERINE L CLELLAND; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The neurodegenerative tauopathies Alzheimer's disease (AD) and Frontotemporal dementia (FTD), are characterized by the intracellular build-up of tau-containing neurofibrillary tangles (NFT), and ..
  33. A conditional model of Neurofibrillary Pathology
    Jada Lewis; Fiscal Year: 2003
    ..The tau neuropathology in these mice is strikingly similar to the neurofibrillary tangles observed in human tauopathies. Although our tau model makes it possible to study the earliest stages of neurodegeneration associated with tau ..
  34. Abnormal Hyperphosphorylation of Tau
    Khalid Iqbal; Fiscal Year: 2007
    ..on this knowledge, identify specific therapeutic targets for Alzheimer disease (AD), Down syndrome and other tauopathies which are characterized by this brain lesion...
  35. The role of microglial-and neuron-specific MyD88 signaling in tauopathies
    Kiran Bhaskar; Fiscal Year: 2012
    ..of microtubule-associated protein tau (MAPT) and neurodegeneration are hallmarks of many neurodegenerative tauopathies. Although, the exact etiology of many of these tauopathies remains elusive, neuropathologically, they are ..
  36. Biochemical and Immunohistochemical Analysis of FTDs
    Virginia Lee; Fiscal Year: 2000
    ..addition to extensive neuron loss and gliosis, are the neuropathological hallmark lesions of neurodegenerative tauopathies including Alzheimer disease (AD), Down's syndrome, progressive supranuclear palsy (PSP), amyotrophic lateral ..
  37. MSUT2/SUT2 controls tau protein aggregation and neurotoxicity.
    Brian C Kraemer; Fiscal Year: 2011
    ..To better understand how abnormal tau contributes to neurodegeneration in AD and other tauopathies, we have established a model in C. elegans for tau aggregation and consequent neurodegeneration...
  38. Kinases Linking Abeta and Tau to Synaptic Dysfunction
    Lennart Mucke; Fiscal Year: 2011
    ..frontotemporal lobar degeneration (FTLD) and a variety of other neurodegenerative conditions referred to as "tauopathies." Preliminary data obtained during the preceding funding period suggest that neuronal and behavioral ..
  39. A kinase pathway required for cortical neuron polarization
    Franck Polleux; Fiscal Year: 2009
    ..Recent evidence suggested that LKB1 disruption could participate to tauopathies such as Alzheimer's disease...
  40. A kinase pathway required for cortical neuron polarization
    Franck Polleux; Fiscal Year: 2010
    ..Recent evidence suggested that LKB1 disruption could participate to tauopathies such as Alzheimer's disease...
  41. Development and Testing of Hsp90 Inhibitors
    Leonard Petrucelli; Fiscal Year: 2010
    ..develop and characterize small compounds called Hsp90 inhibitors as potential therapeutics for the treatment of tauopathies including frontotemporal degeneration...
  42. Elucidating the Pathology of Impact-Induced Traumatic Brain Injury
    CHAD ALAN TAGGE; Fiscal Year: 2012
    ..Insight gained from this work will also facilitate development of urgently needed diagnostics and therapeutics for these devastating disorders. ..
  43. LRRK2 modulates the progression of neuropathology in a mouse model of tauopathy
    Rachel M Bailey; Fiscal Year: 2012
    ..Two such factors, tau and LRRK2, are implicated in PD and disorders termed tauopathies;however, it is unknown if they work together or independently to affect disease progression...
  44. In Search of the Molecular Basis of Memory Loss in Tauopathy
    Karen Ashe; Fiscal Year: 2009
    ....
  45. In Search of the Molecular Basis of Memory Loss in Tauopathy
    Karen H Ashe; Fiscal Year: 2010
    ....
  46. Elucidating the Pathology of Impact-Induced Traumatic Brain Injury
    CHAD ALAN TAGGE; Fiscal Year: 2011
    ..Insight gained from this work will also facilitate development of urgently needed diagnostics and therapeutics for these devastating disorders. ..
  47. Parkin protection in gene transfer animal models (KO-1 Award)
    CHARBEL ELHAJJ MOUSSA; Fiscal Year: 2009
    ..an important pathological landmark in Parkinson's disease [PD], Alzheimer's disease [AD] and the tauopathies with Parkinsonism...
  48. PHOSPHORYLATION CONTROL--TAU NEUROTOXICITY IN DROSOPHILA
    Mel Feany; Fiscal Year: 2004
    ..abstract_text> ..
  49. Mechanisms of Tau-Based Neurodegeneration
    Mark Forman; Fiscal Year: 2002
    ..in neurons, astrocytes and oligodendrocytes are the neuropathological hallmark of both sporadic and familial tauopathies. Alzheimer's disease (AD), the most common tauopathy, is characterized by the deposition of numerous Ap-rich ..
  50. Mechanisms of Tau-Based Neurodegeneration
    Mark Forman; Fiscal Year: 2004
    ..in neurons, astrocytes and oligodendrocytes are the neuropathological hallmark of both sporadic and familial tauopathies. Alzheimer's disease (AD), the most common tauopathy, is characterized by the deposition of numerous Ap-rich ..
  51. Mechanism of CD40 signaling to APP metabolism
    Michael J Mullan; Fiscal Year: 2011
    ..We have identified CD40 signaling as a potentially key modulator of both amyloid and tau pathology and this proposal seeks to identify downstream molecules which are more tractable from a drug development perspective. ..
  52. Epitope-Specific Targeting of Tau Aggregates.
    Einar M Sigurdsson; Fiscal Year: 2011
    ..tau protein has recently become attractive as a potential therapy for Alzheimer's disease (AD) and related tauopathies. We previously showed that active immunization targeting a disease-related phospho-tau epitope reduces cerebral ..
  53. Spatio temporal relationship of pathology and functional decline with tauopathy
    Karen E Duff; Fiscal Year: 2012
    ..Insights from these mice could inform on future diagnostic or therapeutic approaches that could prevent the progression to severe stages. ..
  54. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2003
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  55. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2001
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  56. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2002
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  57. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2004
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  58. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2006
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  59. Suppression of Tauopathy by Lysosomal Activation
    Jason Eriksen; Fiscal Year: 2007
    ..This observation suggests that in Alzheimer's disease and other tauopathies the presence of tangles (a pathological hallmark of these diseases) may be due to the impaired clearance of ..
  60. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2007
    ..PP2A in human brain regions during normal aging, and assess whether it becomes altered in AD and other tauopathies. If our model is validated, dietary folate supplementation and PPMT may be novel therapeutic targets for ..
  61. Role of PP2A in tauopathies
    Estelle Sontag; Fiscal Year: 2005
    ..the hypothesis that their disruption promotes the accumulation of hyperphosphorylated forms of tau in all tauopathies. The first aim will focus on establishing major properties of PP2A/tau and PP2A/MT interactions in vitro and in ..
  62. Hsp90 inhibitors as suppressors of protein misfolding toxicity
    Gabriela Chiosis; Fiscal Year: 2007
    ..formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein are maintained in tauopathies by Hsp90...
  63. Biology of Tauopathies Studied with HSV Amplicons
    Ennio Chiocca; Fiscal Year: 2005
    ....
  64. Biology of Tauopathies Studied with HSV Amplicons
    E Antonio Chiocca; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  65. Biology of Tauopathies Studied with HSV Amplicons
    Ennio Chiocca; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  66. Molecular determinants of lamin a accumulation in human aging and disease
    Agnieszka Kalinowski; Fiscal Year: 2009
    ..other pathologies that result from destructive protein-membrane interactions, such as Alzheimer's disease, tauopathies and prion diseases...
  67. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2005
    The tau H1 association in 4R tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), is fundamental to their etiology, yet the underlying mutation(s) and functional effects on tau biology remain ..
  68. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): The tau H1 association in 4R tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), is fundamental to their etiology, yet the underlying mutation(s) and ..
  69. The Molecular Structure and Function of Tau Protein
    Stuart Feinstein; Fiscal Year: 2007
    ..conclusion that pathological tau action is likely a key component in Alzheimer's, FTDP-17 and additional "tauopathies"...
  70. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2004
    The tau H1 association in 4R tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), is fundamental to their etiology, yet the underlying mutation(s) and functional effects on tau biology remain ..
  71. Structure and Function of Tau Protein
    Stuart Feinstein; Fiscal Year: 2006
    ..conclusion that pathological tau action is likely a key component in Alzheimer's, FTDP-17 and additional "tauopathies"...
  72. Role of the Prolyl lsomerase Pin1 in Alzheimer's Disease
    Kun Ping Lu; Fiscal Year: 2010
    ..In this proposal, we will continue to investigate how this enzyme affects the disease processes and hope to eventually identify new therapeutic targets. ..
  73. Role of the Prolyl lsomerase Pin1 in Alzheimer's Disease
    Kun Ping Lu; Fiscal Year: 2009
    ..In this proposal, we will continue to investigate how this enzyme affects the disease processes and hope to eventually identify new therapeutic targets. ..
  74. Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio
    STEVEN BRAITHWAITE; Fiscal Year: 2010
    ..Abnormal hyperphosphorylation of tau plays an important role in Alzheimer's disease (AD) and other tauopathies. Current therapeutic approaches with focus on tau kinases (e.g...
  75. Development of Radiopharmaceuticals for Imaging Brain Tau Pathology
    Daniel Skovronsky; Fiscal Year: 2009
    ..of Alzheimer's disease and for 2) Improving early and accurate diagnosis of Alzheimer's and related tauopathies. To test this hypothesis, we will screen for and develop a novel 18F-labeled radiopharmaceutical to ..
  76. Role of the Prolyl lsomerase Pin1 in Alzheimer's Disease
    Kun Ping Lu; Fiscal Year: 2007
    ..In this proposal, we will continue to investigate how this enzyme affects the disease processes and hope to eventually identify new therapeutic targets. ..
  77. Alzhelmer's Disease Drug Development Program
    Amos B Smith; Fiscal Year: 2010
    ..system (CMS) are sequestered into filamentous inclusions that are the signature lesions of AD and related tauopathies, thereby compromising the normal function of tau in stabilizing and maintaining MT networks essential for ..
  78. Genetic and Environmental Risk Factors for PSP
    Irene Litvan; Fiscal Year: 2009
    ..Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease...
  79. PROTEIN KINASE MARKERS OF AD PROGRESSION
    JEFFREY KURET; Fiscal Year: 2001
    ..abstract_text> ..
  80. Alzhelmer's Disease Drug Development Program
    AMOS SMITH; Fiscal Year: 2009
    ..system (CMS) are sequestered into filamentous inclusions that are the signature lesions of AD and related tauopathies, thereby compromising the normal function of tau in stabilizing and maintaining MT networks essential for ..
  81. Genetic and Environmental Risk Factors for PSP
    Irene Litvan; Fiscal Year: 2007
    ..Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease...
  82. Genetic and Environmental Risk Factors for PSP
    Irene Litvan; Fiscal Year: 2006
    ..Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease...
  83. Proteome analysis in mice expressing P301L tau
    Irving Vega; Fiscal Year: 2004
    ..These approaches may contribute to the identification of important biological markers involved at early stages of the development of tauopathy and may bring insights into the molecular mechanism underline tau aggregation ..
  84. Neurofibrillary Tangle-Induced Dementia in AD
    Travis Dunckley; Fiscal Year: 2007
    ..without concomitant amyloid pathology in a broad class of neurodegenerative diseases, collectively known as "tauopathies." This suggests that NFTs themselves are intricately involved in neurodegenerative processes...
  85. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2000
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..
  86. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2001
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..
  87. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2001
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..
  88. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2002
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..
  89. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2004
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..
  90. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2003
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..
  91. TAUOPATHIES: GENOTYPE AND PHENOTYPE
    Virginia Lee; Fiscal Year: 2001
    ..create bold new opportunities to elucidate cellular and molecular mechanisms of neurodegenerative diseases (tauopathies) characterized by prominent tau pathologies as well as the role of these pathologies in the progressive ..